

CODICE CONCORSO 2020RTDB035

PROCEDURA SELETTIVA DI CHIAMATA PER N. 1 POSTO DI RICERCATORE A TEMPO DETERMINATO DI TIPOLOGIA B PER IL SETTORE CONCORSUALE 06/H1 - SETTORE SCIENTIFICO-DISCIPLINARE MED/40 - PRESSO IL DIPARTIMENTO MATERNO INFANTILE E SCIENZE UROLOGICHE DELL'UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" BANDITA CON D.R. N. 3188/2020 DEL 15.12.2020

VERBALE N. 2 – SEDUTA VERIFICA TITOLI

L'anno **2021**, il giorno **24** del mese di **giugno** in Roma si è riunita nei locali del Dipartimento Materno Infantile e Scienze Urologiche (Direzione – piano terra – Edificio di Ginecologia e Ostetricia) la Commissione giudicatrice della procedura selettiva di chiamata per n. 1 posto di Ricercatore a tempo determinato di tipologia B per il Settore concorsuale 06/H1 – Settore scientifico-disciplinare MED/40 - presso il Dipartimento Materno Infantile e Scienze Urologiche dell'Università degli Studi di Roma "La Sapienza", nominata con D.R. n. 1108/2021 del 23.4.2021 e composta da:

- Prof. Ludovico Muzii – professore ordinario presso il Dipartimento Materno Infantile e Scienze Urologiche di Sapienza Università di Roma (Presidente);
- Prof.ssa Rossella Nappi – professore ordinario presso il Dipartimento di Scienze Clinico-Chirurgiche, Diagnostiche e Pediatriche dell'Università degli Studi di Pavia (Componente);
- Prof. Francesco Plotti – professore associato presso il Dipartimento di Medicina e Chirurgia dell'Università Campus Bio-Medico di Roma (Segretario).

Il Prof. Muzii è fisicamente presente, mentre la Prof.ssa Nappi e il Prof. Plotti sono collegati per via telematica tramite collegamento Google Meet al seguente link: meet.google.com/kdt-onaw-sua.

La Commissione inizia i propri lavori alle ore 9.00.

Il Presidente informa la Commissione di aver acquisito dal Responsabile del procedimento l'elenco dei candidati ammessi con riserva alla procedura selettiva e la documentazione, in formato elettronico, trasmessa dagli stessi.

Il Presidente informa, altresì, che il Dott.ssa Di Tucci Chiara ha presentato in data 21/06/2021, con PEC prot. N. 00488883 dichiarazione di rinuncia alla partecipazione alla presente procedura selettiva.

La Commissione giudicatrice dichiara sotto la propria responsabilità che tra i componenti della Commissione ed i candidati non sussistono rapporti di coniugio, di parentela o di affinità, fino al quarto grado compreso, né altre situazioni di incompatibilità ai sensi degli artt. 51 e 52 del Codice di Procedura Civile e dell'art. 18, primo comma, lett. b) e c), della legge 30 dicembre 2010, n. 240.

I candidati alla procedura selettiva risultano essere i seguenti:

- 1) TOMAO Federica, Nata il 30/04/1981

La Commissione, quindi, procede ad esaminare le domande di partecipazione alla procedura presentate da parte dei candidati, con i titoli allegati e le pubblicazioni.

Per ogni candidato, la Commissione verifica che i titoli allegati alla domanda siano stati certificati conformemente al bando.

Procede poi ad elencare analiticamente i titoli e le pubblicazioni trasmesse dal candidato.

Successivamente elenca, per ogni candidato, i titoli e le pubblicazioni valutabili (allegato B).

Vengono esaminati i titoli e le pubblicazioni del candidato TOMAO Federica.

La Commissione termina i propri lavori alle ore 9.30 e si riconvoca per la verifica dei titoli e delle pubblicazioni dei candidati, il giorno 24 giugno 2021 alle ore 9.40

Letto, confermato e sottoscritto.

Firma del Commissari

Prof. Ludovico Muzii (Presidente)

Prof.ssa Rossella Nappi (Componente)

Prof. Francesco Plotti (Segretario)

ALLEGATO B AL VERBALE N. 2

CODICE CONCORSO 2020RTDB035

PROCEDURA SELETTIVA DI CHIAMATA PER N. 1 POSTO DI RICERCATORE A TEMPO DETERMINATO DI TIPOLOGIA B PER IL SETTORE CONCORSUALE 06/H1 - SETTORE SCIENTIFICO-DISCIPLINARE MED/40 - PRESSO IL DIPARTIMENTO MATERNO INFANTILE E SCIENZE UROLOGICHE DELL'UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA" BANDITA CON D.R. N. 3188/2020 DEL 15.12.2020

TITOLI E PUBBLICAZIONI VALUTABILI

CANDIDATO: TOMAO FEDERICA

VERIFICA TITOLI VALUTABILI:

presa d'atto dei titoli – es. dottorato, specializzazione, attività didattica, etc – per i quali sia stata presentata idonea documentazione.

A. TESI DI DOTTORATO:

PhD Degree in Gynecology & Obstetrics (Ciclo XXVI) Ruolo della linfadenectomia inguinale nel carcinoma vulvare: fattori prognostici correlati allo status linfonodale. Sapienza University of Rome
Dept. of Gynecological- Obstetrical Sciences and Urological Sciences

B. ATTIVITÀ DIDATTICA:

1. Professor of Physiology (Seminars) from 2005 to 2008 University of Cassino. School of 2008 Sport Sciences.
2. Sapienza University. School of Nursing. Section of Pomezia, Official Professor of Gynecology and Obstetrics in the Course of Nursing in maternal and pediatric area
3. Sapienza University. School of Nursing. Section of Pomezia, Integrative teaching activity in the Course of Nursing in maternal and pediatric area (MED/40)
4. University of Cassino. School of Sport Sciences, Integrative teaching activity in the Course of Clinical Sciences applied to sport activities
5. Sapienza University. School of Pharmacy and Medicine. Course E of Medicine and Surgery Integrative teaching activity in the Course of Internal Medicine and General Surgery 1(Gynecologic

Oncology / MED/40)

- 6.** Sapienza University. School of Pharmacy and Medicine Course C of Nursing, Policlinico Umberto 1 Seminar and Integrative teaching activity (Gynecology and Obstetrics) MED/40
- 7.** Sapienza University. School of Pharmacy and Medicine. Course of Nursing of Frosinone Seminar and Integrative teaching activity (Gynecology and Obstetrics) MED/40
- 8.** Sapienza University. School of Pharmacy and Medicine. Course E of Medicine and Surgery Integrative teaching activity in the integrated course of Gynecology and Obstetrics MED/40
- 9.** Sapienza University. School of Pharmacy and Medicine. Course R of Nursing of Terracina Seminar and Integrative teaching activity (Gynecology and Obstetrics) MED/40
- 10.** Sapienza University. School of Pharmacy and Medicine. Course of Nursing of Pomezia. Integrated Course of Nursing in maternal and pediatric area Official Holder (Contract Professor) of Gynecology and Obstetrics MED/40
- 11.** Sapienza University. School of Medicine and Odontology. Course of Medicine and Surgery D Integrative teaching activity in the integrated course of Gynecology and Obstetrics. MED/40
- 12.** Sapienza University. School of Pharmacy and Medicine. School of Nursing Latina. Course General and applied hygiene. Official Holder (Contract Professor) of Prevention and epidemiology in Gynecology, MED/40
- 13.** Sapienza University. School of Medicine and Odontology. Course of Medicine and Surgery A Integrative teaching activity in the integrated course of Gynecology and Obstetrics. MED/40
- 14.** Sapienza University. School of Psychology and Medicine. Course of Nursing and therapeutic processes in maternal and pediatric area. Celio Hospital MED/47 Official Holder (Contract Professor) of Gynecology and Obstetrics. MED/47
- 15.** Sapienza University. School of Medicine and Odontology Official Holder (Contract Professor) MED/47 of Gynecology , Obstetrics Therapy of neuro and psychomotricity of the evolutionary age.
- 16.** University of Rome 3. Chair of Microbiology Seminar "HPV-induced oncogenesis", within thematic issue "Infection and cancer" PhD Course "Biologia applicata alla salute dell'uomo" (PhD Programme in biology applied to human health).

- 17.** University of Rome 3. Chair of Microbiology Seminar“ nnovation protocols against human papilloma virus induced oncogenesis”, within thematic issue “Infection and cancer” Corso di Dottorato di ricerca " Scienze e Tecnologie Biomediche” (PhD Programme in Biomedical^[1]Sciences and Technologies).
- 18.** Dipartimento di Scienze Ginecologico-Ostetriche e Scienze Urologiche. Latina Sapienza Università di Roma Seminar in PhD Course in MEDICINA SPERIMENTALE- TECNOLOGIE INNOVATIVE IN MEDICINA TRASLAZIONALE Il ruolo dei Parp Inhibitors nel carcinoma dell'ovaio.
- 19.** Università degli Studi di Chieti, Gabriele D’Annunzio Seminar in PhD Course in MEDICINA TRASLAZIONALE XXXII ciclo, " Peculiarità dei tumori dell'ovaio BRCA mutati".
- 20.** Terza Clinica Chirurgica, Università di Roma Sapienza, Seminar in PhD Course in Tecnologie avanzate in chirurgia, "TUMORI BRCA MUTATI".
- 21.** Corso di dottorato di ricerca in scienze e tecnologie biomediche PhD programme in biomedical sciences and technologies, Seminar “Sexually transmitted bacterial infections; the clinician’s viewpoint” within the the course “SpecialMicrobiology” for the Master students in “Biologia per la Ricerca Cellulare, Molecolare e Fisiopatologica” of Roma Tre University.
- 22.** Sapienza University. School of Pharmacy and Medicine. Terracina Section. Official Holder (Contract Professor) MED/40 in the Master (first level) in “Nursing assistance in operating room for specialist surgery.

C. ATTIVITÀ DI FORMAZIONE O RICERCA PRESSO QUALIFICATI ISTITUTI.

- 1.** Experimental and clinical Research in Obstetrics & Gynecology, Oncology, Immunology. Sapienza University of Rome Dept. of Gynecological- Obstetrical Sciences and Urological Sciences
- 2.** Clinical and research experience in Gynecology Oncology and Medical Oncology (Prof. R.De Maria, dr. P.Vici) National Cancer Institute of Rome Regina Elena
- 3.** Clinical and research experience in Immunology (Prof.M. Nuti Lab) Sapienza University of Rome
- 4.** Clinical research in Gynecology and Obstetrics Giovanni XXIII Hospital Dept. Gynecology and Obstetrics, Bergamo (Prof. L. Frigerio)

- 5.** Clinical and research experience in Perinatal Medicine, from 14th february to 6th june 2008 Harris Birthright Center for fetal medicine” at King’s College Hospital of London (Prof. K. Nicolaides)
- 6.** Research training in Cancer Medicine from 9/6/08 to 20/6/2008 King’s College Hospital of London^[1]Stem cells Lab (prof. SD. Mingher)
- 7.** Research and clinical research in ovarian cancer and gynecologic oncology National Institute of Health Dipartimento di Oncologia, Ematologia e Medicina Molecolare (Prof. R.De Maria, Prof. Ugo Testa)
- 8.** Research and clinical research in ovarian cancer and gynecologic oncology Istituto Farmacologico Mario Negri.
- 9.** Research Fellow. Topic: Alterazioni dei meccanismi di risposta al danno del DNA come bersaglio terapeutico per i tumori ginecologici. Department of Molecular Medicine
- 10.** Research Fellow. Topic:Identificazione di pattern molecolari coinvolti nella patogenesi dei tumori ovarici sierosi BRCA1-2 mutati e sporadici: implicazioni cliniche e terapeutiche future. Sapienza University of Rome Dept. Maternal Infantile and Urological Sciences
- 11.** Research Fellow. Topic: Targeted therapies in epithelial ovarian cancer. Sapienza University of Rome Department of Sciences and Medical Surgical Biotechnologies
- 12.** Research Fellow. Identification of molecular alterations related to the pathogenesis of ovarian tumors in BRCA1-2 mutated patients. European Institute of Oncology
- 13.** Research Fellow for the study and Research in Gynecological and peritoneal cancer. University of Heraklion, Greece Department of Gynecology and Surgical Oncology
- 14.** Founding and Secretary Member of Scientific Committee and consultant for experimental and clinical evaluation of biotechnologic agents in gynecologic oncology. University of Chieti Gabriele D’Annunzio. Spin off MediaPharma Srl.
- 15.** Research Fellow. Topic: Identification of new potential biomarkers of HGSOG: a comparison of phenotypic and metabolic profile among BRCA mutated and wild type population. Sapienza University of Rome. Dept. Maternal Infantile and Urological Sciences (ex Dept. of Gynecological-Obstetrical Sciences and Urological Sciences).

- 16.** Consultant and scientific collaborator (Tutor prof. Nicoletta Colombo) European Institute of Oncology Department of Gynecologic Oncology
- 17.** Fellowship by ESGO and Fondazione IEO-CCM (Identification of Molecular alteration involved in the pathogenesis of sporadic and BRCA mutated ovarian tumors (Tutor prof. Nicoletta Colombo) European Institute of Oncology Department of Gynecologic Oncology
- 18.** Scientific Consultant in the project “Technological and traslational innovations in the diagnosis and therapy of ovarian tumors” Azienda Ospedaliera S.Andrea, Roma Dept. Medical Oncology-Sapienza University (Prof. Paolo Marchetti
- 19.** Clinical Consultant in Gynecology for crews employed in airlines and ships, Ministry of Health-SASN Service

D. ATTIVITÀ IN CAMPO CLINICO:

- 1. Clinical Consultant in Gynecology for crews employed in airlines and ships Ministry of Health-SASN Service.
- 2. CO.CO.CO presso l'Azienda Ospedaliera ed Universitaria Sant'Andrea di Roma, Divisione di Oncologia Medica.
- 3. Consultant and scientific collaborator (Tutor prof. Nicoletta Colombo) European Institute of Oncology Department of Gynecologic Oncology.
- 4. Research Fellow Sapienza University of Rome. Dept. Maternal Infantile and Urological Sciences (ex Dept. of Gynecological-Obstetrical Sciences and Urological Sciences).

E. REALIZZAZIONE DI ATTIVITÀ PROGETTUALE

- 1. Investigator in the Scientific project of information, health education and oncological training for teachers of High School. A Research project funded by Italian League against cancer.
- 2. Investigator in the Scientific Project “Prevention of ereditary breast/ovarian cancer, risk perception, tailored diagnosis and comunication for compliance improving
- 3. Investigator in the Scientific Project “Cardiac function, levels of pro-inflammatory molecules related to long time use of erythropoietin.

4. Investigator in several research projects started by the collaboration between Dept. of Gynecology and Dept. of Experimental Medicine of Sapienza University in the field of gynecologic oncology and immunology (Prof. Benedetti Panici and Nuti).
5. Analysis of immunosuppressive TREG cells as prognostic indicator in patients with ovarian cancer” PRIN Research project funded by MIUR, protocol n: 2009XMZPKW_005 24 UNIT UNIT B
6. “Evaluation of T cell Population by phenotypic and functional point of view during the tumor progression, chemotherapy and tumor-associated vaccination” PRIN Research project funded by MIUR, protocol n: 20072LRAZJ_005
7. “Characterization of molecular and immunological tumor progression markers by a prognostic and therapeutical point of view in ovarian cancer PRIN Research project funded by MIUR, protocol n: RBFR08HCAL_001
8. Evaluation of combined activity of Doxorubicin or Etoposide with LBW242 in the relapse of platinum resistant ovarian cancer Research projects funded by Sapienza University of Rome Research starting grant for Young researchers
9. “Effect of metformin in treating patients with cervical cancer undergoing neoadjuvant platinum-based chemotherapy followed by radical surgery” Research projects funded by Sapienza University of Rome Research starting grant for Young researchers
10. “Identification of Biological Prognostic Factors and Potential Therapeutic Targets in Endometrial Cancer” Research projects funded by Sapienza University of Rome.
11. “Very early 2D/3D transvaginal ultrasound evaluation to predict response to neoadjuvant chemotherapy in locally advanced cervical cancer” Research projects funded by Sapienza University of Rome Research starting grant for Young researcher.
12. Preoperative management in Obstetrical and Gynecological: Free diet vs diet without steroids. A randomized clinical study Research projects funded by Sapienza University of Rome 2018 number of protocol number P1181642D95BD92
13. Integration of Multiparametric MR imaging and multi-omics based approaches to address High Grade Serous Ovarian Cancer patients towards Neoadjuvant or Adjuvant treatment. Research projects funded by Ministry of Health 2019. Ricerca Finalizzata. Under evaluation.

14. Investigator dell'Istituto Europeo di Oncologia per il work package 4 del progetto Alleanza Contro il cancro. Titolo: Studi di fattibilità per la realizzazione di piattaforme clinico scientifiche di Precision Oncology. WP 4 G VERSO la diagnosi precoce del carcinoma ovarico sieroso di alto grado mediante l'analisi delle varianti lomiali di TP53 nel Pap test (progetto TOWARDS). Grant RCG 2020GRETEACCGWP4GTOMAO

15. Co-Investigatore nel progetto "BAROCCO" The BAROCCO study Approach in Resistant Ovaria with Cediranib (Olaparib): uno studio italiano multicentrico, randomizzato II che confronta paclitaxel settimana Cediranib (Olaparib) in regime continuo Cediranib (Olaparib) in regime intermittente nelle pazienti con carcinoma di alto platino resistente dell'ovaio/tubo falloppio/peritoneo.

F. GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI

- Member of The Endocrine Society
- Member of European Society of Gynecologic Oncology (ESGO)
- Member of Associazione Italiana di Oncologia Medica - (AIOM)
- Member of European Society of Medical Oncology - [SEP] Member of Società Italiana di Ginecologia ed Ostetricia - [SEP] Member of Società Italiana di Diagnostica Prenatale e Medicina Materno-Fetale
- Member of Società Italiana di Medicina Personalizzata-SIMEP [SEP] Member of American Association for Cancer Research (AACR)
- Member of MITO Group for the development of scientific research and clinical trials today in Gynecologic Oncology [SEP] Member of MANGO Group for the development of scientific research and clinical today trials in Gynecologic Oncology [SEP] Member at 2018 ENGOT academy for MANGO group.
- Founder and member of Network "Ymagine".
- Fondazione Federico Calabresi Award for the best paper presented at Modena
- International Breast cancer conference 15-17 settembre 2010

G. BREVETTI

Nessuno

H. RELAZIONI A CONGRESSI NAZIONALI E INTERNAZIONALI:

Relatrice a 65 congressi totali di cui 14 internazionali.

Relatrice a 39 congressi negli ultimi 5 anni, di cui 8 internazionali.

Presentazione di 60 abstract e poster a congressi nazionali ed internazionali, di cui 13 negli ultimi 5 anni.

I. VERIFICA PUBBLICAZIONI VALUTABILI

1. Colombo I, Zaccarelli E, Del Grande M, Tomao F, Multinu F, Betella I, Ledermann JA, Gonzalez- Martin A, Sessa C, Colombo N. ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. ESMO Open. 2020 Jul;5(Suppl 3):e000827. doi: 10.1136/esmoopen-2020-000827. Impact Factor 5,329 Citations
2. Tomao F, Santangelo G, Musacchio L, Di Donato V, Fischetti M, Gi Tomao F, Santangelo G, Musacchio L, Di Donato V, Fischetti M, Giacotti A, Perniola G, Petrella MC, Monti M, Palaia I, Muzii L, Benedetti Panici P. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition? J Cell Physiol. 2020 Jun;235(6):5050- 5058. doi:10.1002/jcp.29440. Epub 2020 Jan 8. Impact Factor 5,546 Citations 5
3. Palaia I, Tomao F, Santangelo G, Di Pinto A, Sassu CM, Perniola G, Musella A, Di Donato V, Giacotti A, Benedetti Panici P. The EOLO (End-of-Life Ovarian Cancer) Study: Approach to Ovarian Cancer Patients at the End of Life. Oncology. 2019 Aug 22:1-5. doi: 10.1159/000501721. Impact Factor: 2,642 Citations 2
4. Di Donato V, Di Pinto A, Giannini A, Caruso G, D'Oria O, Tomao F, Fischetti M, Perniola G, Palaia I, Muzii L, Benedetti Panici P. Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol. 2020 Sep 4:S0090-8258(20)33823-3. doi: 10.1016/j.ygyno.2020.08.022. Impact Factor 4,623 Citations 1
5. Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V, Tomao F. Bevacizumab in ovarian cancer: A critical review of phase III studies. Oncotarget, 2017 Feb 14;8(7):12389-12405. doi: 10.18632/oncotarget.13310. Impact Factor: 5,168 citations 51
6. Tomao F, Maruccio M, Preti EP, Boveri S, Ricciardi E, Zanagnolo V, Landoni F. Conization in Early Stage Cervical Cancer: Pattern of Recurrence in a 10-Year Single-Institution Experience. International journal of gynecological cancer 2017, 27, 1001-1008 Impact Factor: 2,192 citations 14

7. Davide Caruso, Anselmo Papa, Silverio Tomao, Patrizia Vici, Pierluigi Benedetti Panici and Federica Tomao. Niraparib in ovarian cancer: results to date and clinical potential. *Therapeutic Advances in Medical Oncology*. 2017, Vol. 9(9) 579-588. Impact Factor: 6,238 citations 16
8. Federica Tomao, Maurizio D'Incalci, Elena Biagioli, Chem. Pharm. D, Fedra A. Peccatori and Nicoletta Colombo. Restoring Platinum Sensitivity in Recurrent Ovarian Cancer by Extending the Platinum-Free Interval: Myth or Reality? *Cancer*, 2017 Sep 15;123(18):3450-3459. Impact Factor: 6,537 citations 14
9. Tomao F, Papa A, Tomao S. Breast Cancer Risk After Ovarian Stimulation for In Vitro Fertilization. *JAMA*, 2016 Oct 25;316(16):1713. doi: 10.1001/jama.2016.7524. Impact Factor: 45,050 Citations
10. Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G, Zanagnolo V, Del Grande M, Colombo N, Bellomi M. Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. *Eur Radiol*. 2018 Nov;28(11):4849-4859. doi: 10.1007/s00330-018-5389-2. Impact Factor 3,962 Citations 32
11. Lazzari & Ronchi S, Gandini S, Surgo A, Volpe S, Piperno G, Comi S, Pansini F, Fodor C, Orecchia R, Tomao F, Parma G, Colombo N, Fereczek-Fossa BA. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. *Int J Radiat Oncol Biol Phys*. 2018 Jul 1; 101(3): 650-660. doi: 10.1016/j.ijrobp.2018.03.058, Impact Factor 6,203 Citations 26
12. Papa A, Caruso D, Strudel M, Tomao S, Tomao F. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. *J Transl Med*. 2016 Sep 15;14:267. doi: 10.1186/s12947-016-0071-1. Impact Factor 3,786 Citations 48
13. Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. *Cancer Treat Rev*. 2019 Oct 9;80:101909. doi: 10.1016/j.ctrv.2019.10.009. Impact Factor 8,885 Citations 15

14. Tomao F, Benedetti Panici P, Tomao S. Adjuvant Therapy for Early Uterine High- Grade Leiomyosarcoma. *J Clin Oncol*. 2019 Apr 10;37(11):935-936. doi: 10.1200/JCO.2018.01990. Epub 2019 Feb 27. PubMed PMID: 3081297. Impact Factor: 32,956 Citations 1
15. Tomao F, Peccatori F, Del Pup L, Franchi D, Zanagnolo V, Panici PB, Colombo N. Special issues in fertility preservation for gynecologic malignancies. *Crit Rev Oncol Hematol*. 2016 Jan;97:206-19. doi: 10.1016/j.critrevonc.2015.08.024. Epub 2015 Sep 8. PubMed PMID: 26338422. Impact Factor: 4,97 Citations 32
16. Papa A, Zaccarelli E, Caruso D, Vici P, Benedetti Panici P, Tomao F. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. *Expert Opin Investig Drugs*. 2016;25(1):31-49. doi: 10.1517/17354378.2016.1176517. PubMed PMID: 26560489. Impact Factor: 4,716 Citations 16
17. Tomao F, Marchetti C, Romito A, Di Pinto A, Di Donato V, Capri O, Palaia I, Monti M, Muzii L, Benedetti Panici P. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies. *Expert Opin Pharmacother*. 2017 Oct;18(10):1443-1455. doi: 10.1080/14656566.2017.1328055. Epub 2017 Aug 18. Review. PubMed PMID: 29251614. Impact Factor: 5,107 Citations 14
18. Tomao F, Vici P, Tomao S. Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial. *Lancet Oncol*. 2020 May;21(5):666-676. doi: 10.1016/S1473-0245(20)30079-6. Impact Factor 33,7 Citations 5
19. Perniola G, Tomao F, Graziano M, Palaia I, Fischetti M, Lecce F, Casorelli A, Di Donato V, Giacchetti A, Battaglia FA, Muzii L, Benedetti Panici P. The Role of 2D/3D Ultrasound to Assess the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. *Oncology*. IF: 2,642 Citation
20. Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F, Lapresa MT, Maruccio M, Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A. Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. *Anticancer Res*. 2017 Sep;37(9):5241-5248. PubMed PMID: 28870960. Impact Factor 1,865 Citations 5

21. Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? *Gynecol Oncol*. 2019 Jul;154(1):138-143. doi: 10.1016/j.ygyno.2019.04.009. Impact Factor 4.623 Citations 4
22. Fumagalli C, Tomao F, Betella I, Rappa A, Calvello M, Bonanni B, Bernard L, Peccatori F, Colombo N, Viale G, Barberis M, Guerini-Rocco E. Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. *Cancers (Basel)*. 2019 Oct 24;11(10):1641. doi: 10.3390/cancers11111641. Impact Factor 6.126 Citations 4
23. Rossi L, Verrico M, Tomao S, Ricci F, Fontana A, Spinelli GP, Colonna M, Vici P, Tomao F. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. *Cancer Chemother Pharmacol*. 2020 Jan;85(1):105-111. doi: 10.1007/s00280-019-03981-5. Impact Factor 2.967 Citations 2
24. Tomao F, Corrado G, Peccatori FA, Boveri S, Preti EP, Colombo N, Landoni F. Fertility-Sparing Options in Young Women with Cervical Cancer. *Curr Treat Options Oncol*. 2016 Jan;17(1):5. doi: 10.1007/s11864-015-0386-9. Review. PubMed PMID: 26810054. Impact Factor: 2.820 Citations 17
25. Napoletano C, Steentoff C, Battisti F, Ye Z, Rahimi H, Zizzari IG, Dionisi M, Cerbelli B, Tomao F, French D, d'Amati G, Panici PB, Vakhrushev S, Clausen H, Nuti M, Rughetti A. Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL). *Cancers (Basel)*. 2020 Oct 1;12(10):2841. doi: 10.3390/cancers12102841. Impact Factor 6.26 Citations 1

CONSISTENZA COMPLESSIVA DELLA PRODUZIONE SCIENTIFICA:

Il candidato presenta una produzione complessiva pari a:
 140 pubblicazioni indexate su scopus.
 1 Capitolo di Libri.
 Total Impact factor: 705,319
 Total Citation: 2109
 Hirsch (H) index: 24
 Normalized H index: 1,5

Letto, confermato e sottoscritto.

Firma del Commissari

Prof. Ludovico Muzii	(Presidente)
Prof.ssa Rossella Nappi	(Componente)
Prof. Francesco Plotti	(Segretario)